膀胱癌经尿道电切标本淋巴血管侵犯的系统综述与荟萃分析
该系统综述与荟萃分析检索近10年文献,纳入33项研究共6194例患者,评估经尿道电切标本中淋巴血管侵犯(LVI)的预后价值。结果显示LVI在TUR标本中检出率为17.3%,在≤cT1期患者中为15%;≤cT1期患者LVI是疾病复发(汇总HR 1.97,95%CI 1.47-2.62)和进展(汇总HR 2.95,95%CI 2.11-4.13)的显著预后因素。
要点
- TURBT标本LVI检出率17.3%,≤cT1期患者为15%。
- ≤cT1期患者LVI显著预测复发(HR 1.97)和进展(HR 2.95)。
- cT1-2期患者LVI与根治性膀胱切除时分期上调相关(OR 2.39)。
核心结论
- TURBT标本中LVI是非肌层浸润性膀胱癌复发和进展的稳健预后因素。
- LVI对器官局限性疾病的分期上调有强烈影响。
- 建议标准化评估并报告LVI,考虑纳入TNM分类系统。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane图书馆2017年8月前10年文献。
- 方案注册于PROSPERO(CRD42018084876)。
- 纳入33项研究,共6194例评估TUR标本LVI的患者。
主要发现
- TUR标本中LVI检出率为17.3%。
- 19项研究仅纳入≤cT1期患者共2941例,LVI检出率为15%。
- ≤cT1期患者LVI预测疾病复发汇总HR 1.97(95%CI 1.47-2.62),异质性I2=0.0%,P=0.84。
- ≤cT1期患者LVI预测疾病进展汇总HR 2.95(95%CI 2.11-4.13),异质性I2=0.0%,P=0.93。
- cT1-2期患者LVI与根治性膀胱切除时分期上调相关,汇总OR 2.39(95%CI 1.45-3.96),异质性I2=53.6%,P=0.044。
临床怎么用
- 对TURBT标本应标准化评估并报告LVI,辅助风险分层。
- ≤cT1期患者若检出LVI,应视为复发和进展高危,加强决策与咨询。
- cT1-2期患者LVI提示根治性膀胱切除时分期上调风险,可指导治疗选择。
局限性
- 各研究间在cT1-2期分期上调分析中存在异质性(I2=53.6%,P=0.044)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of the present review was to assess the prognostic impact of lymphovascular invasion (LVI) in transurethral resection (TUR) of bladder cancer (BCa) specimens on clinical outcomes. A systematic review and meta-analysis of the available literature from the past 10 years was performed using MEDLINE, EMBASE and Cochrane library in August 2017. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42018084876) and is available in full on the University of York website. Overall, 33 studies (including 6194 patients) evaluating the presence of LVI at TUR were retrieved. LVI was detected in 17.3% of TUR specimens. In 19 studies, including 2941 patients with ≤cT1 stage only, LVI was detected in 15% of specimens. In patients with ≤cT1 stage, LVI at TUR of the bladder tumour (TURBT) was a significant prognostic factor for disease recurrence (pooled hazard ratio [HR] 1.97, 95% CI: 1.47-2.62) and progression (pooled HR 2.95, 95% CI: 2.11-4.13), without heterogeneity (I2 = 0.0%, P = 0.84 and I2 = 0.0%, P = 0.93, respectively). For patients with cT1-2 disease, LVI was significantly associated with upstaging at time of radical cystectomy (pooled odds ratio 2.39, 95% CI: 1.45-3.96), with heterogeneity among studies (I2 = 53.6%, P = 0.044). LVI at TURBT is a robust prognostic factor of disease recurrence and progression in non-muscle invasive BCa. Furthermore, LVI has a strong impact on upstaging in patients with organ-confined disease. The assessment of LVI should be standardized, reported, and considered for inclusion in the TNM classification system, helping clinicians in decision-making and patient counselling.
引用
- Mari A, Kimura S, Foerster B, et al. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int. 2018. PMID: 29807387. doi:10.1111/bju.14417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。